MS Briefs

Brief-Smell Identification test: A potential prognostic marker for progressive MS


 

Key clinical point: In patients with progressive multiple sclerosis (MS), impaired odor identification is associated with a greater clinical decline and higher risk for death.

Major finding: Impaired Brief-Smell Identification (B-SIT) was associated with higher risk for death (adjusted hazard ratio [aHR], 14.9; P less than .001). Among patients with progressive MS, impaired B-SIT vs normal B-SIT showed greater clinical change per month in terms of Multiple Sclerosis Severity scores (median, 0.62 vs. –0.08; P =.004) and Age-Related Multiple Sclerosis Severity scores (median, 0.54 vs. –0.07; P =.004).

Study details: Findings from a retrospective review on 149 patients with MS during a median follow-up of 121 months.

Disclosures: No funding source was identified. The authors declared no conflicts of interest.

Citation: da Silva AM et al. Mult Scler Relat Disord. 2020 Sep 3. doi: 10.1016/j.msard.2020.102486 .

Recommended Reading

Rituximab vs. glatiramer acetate for secondary progressive multiple sclerosis
ICYMI Multiple Sclerosis
Newer DMTs are more effective than injectable DMTs in pediatric MS
ICYMI Multiple Sclerosis
When Female Patients with MS Ask About Breastfeeding, Here’s What to Tell Them
ICYMI Multiple Sclerosis
NfL blood biomarker captures suboptimal treatment response in MS
ICYMI Multiple Sclerosis
Pregnancy delays onset of multiple sclerosis symptoms
ICYMI Multiple Sclerosis
Cladribine vs. other disease-modifying drugs in multiple sclerosis
ICYMI Multiple Sclerosis
Multiple sclerosis and the risk for cancer
ICYMI Multiple Sclerosis
Fingolimod vs. glatiramer acetate for relapsing-remitting MS
ICYMI Multiple Sclerosis
Long-term safety and efficacy of teriflunomide for relapsing MS
ICYMI Multiple Sclerosis
MS: Early evaluation of respiratory muscle functions is warranted
ICYMI Multiple Sclerosis